SignalXSignalX

ZYME Zymeworks Inc.

Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Zymeworks Inc. Overview

Zymeworks Inc. (ZYME) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New risk: European Commission granted conditional marketing authorization of Ziihera® in July 2025, contingent on ongoing Phase 3 trial results
  • • Material update: FDA accelerated approval of Ziihera® in Nov 2024 requires confirmatory trial; failure may lead to market removal impacting royalties
+3 more insights

Get deeper insights on Zymeworks Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.